Acaterin | 144398-20-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Acaterin
• 英文别名: (R)-3-((R)-1-hydroxyoctyl)-5-methylfuran-2(5H)-one；3-(1-Hydroxyoctyl)-5-methyl-2(5H)-furanone；(2R)-4-[(1R)-1-hydroxyoctyl]-2-methyl-2H-furan-5-one
• CAS: 144398-20-9
• 化学式: C₁₃H₂₂O₃
• 分子量: 226.316
• InChiKey: YUMHJXLSSASJGN-ZYHUDNBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  methyl 3-hydroxy-2-methylenedecanoate 在 4-二甲氨基吡啶 、 lithium hydroxide 、 Grubbs catalyst first generation 、 四氯化钛 、 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 110.0h， 生成 Acaterin
  参考文献：
  名称：

  Elaboration of a Baylis–Hillman adduct to (−)-acaterin and its diastereomer through ring closing metathesis

  摘要：

  A short and efficient synthesis of acaterin, a biologically important natural product has been achieved by elaboration of a Baylis-Hillman adduct. The key step for the synthesis is a ring closing metathesis reaction using Grubbs' catalyst. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(02)01069-9

文献信息

• Tellurium in organic synthesis: a general approach to buteno- and butanolides
  作者：Renan S. Ferrarini、Alcindo A. Dos Santos、João V. Comasseto

  DOI：10.1016/j.tet.2012.09.074

  日期：2012.12

  The naturally occurring butanolides (−)-blastmycinolactol, (+)-blastmycinone, (−)-NFX-2, (+)-antimycinone as well as the four stereoisomers of the butenolide Acaterin were prepared in high enantiomeric purity using hydroxy-vinyl tellurides as starting materials.

  使用羟基-乙烯基碲化物以高对映体纯度制备了天然存在的丁醇化物（-）-blastmycinactactol，（+）-blastmycinone，（-）-NFX-2，（+）-anticincinone以及丁烯内酯Acaterin的四种立体异构体。作为起始原料。
• [EN] POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS POLYMÉRIQUES HYPERBRANCHÉS
  申请人：ASCENDIS PHARMA AS

  公开号：WO2013024048A1

  公开（公告）日：2013-02-21

  The present invention relates to water-soluble carrier-linked prodrugs of formula (I),wherein POL is a polymeric moiety,each Hyp is independently a hyperbranched moiety,each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water- soluble carrier-linked prodrugs and methods of treatment.

  本发明涉及水溶性载体连接的前药，其化学式为（I），其中POL是聚合物基团，每个Hyp是独立的超支化基团，每个基团SP是独立的间隔基团，每个L是独立的可逆前药连接基团，m为0或1，每个n是独立的整数，范围从2到200，每个x是独立的0或1。此外，还涉及包含所述水溶性载体连接的前药的药物组合物和治疗方法。
• [EN] HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS HYDROSOLUBLES DE FORTE CHARGE
  申请人：ASCENDIS PHARMA AS

  公开号：WO2013024047A1

  公开（公告）日：2013-02-21

  The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein B, A and Hyp form the carrier, B is a branching core, each A is independently a poly(ethylene glycol)-based polymeric chain, each Hyp is independently a branched moiety, each SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, each D is independendly a biologically active moiety, each x is independently 0 or 1, each m is independently an integer of from 2 to 64, n is an integer from 3 to 32; or the pharmaceutically acceptable salt thereof. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs, their use asmedicament or diagnostic, and methods of treatment.

  本发明涉及水溶性载体连接的前药，其化学式为(I)，其中B、A和Hyp形成载体，B是一个分支核心，每个A独立地是一条聚乙二醇基聚合链，每个Hyp独立地是一个分支基团，每个SP独立地是一个间隔基团，每个L独立地是一个可逆前药连接基团，每个D独立地是一个生物活性基团，每个x独立地为0或1，每个m独立地是从2到64的整数，n是从3到32的整数；或其药学上可接受的盐。进一步涉及包括所述水溶性载体连接的前药的药物组合物，其用作药物或诊断，以及治疗方法。
• Synthesis of all the four possible stereoisomers of acaterin, naturally occurring ACAT inhibitor, and the determination of its absolute configuration
  作者：Ken Ishigami、Takeshi Kitahara

  DOI：10.1016/0040-4020(95)00303-p

  日期：1995.6

  synthesis of all the possible stereoisomers of acaterin 1, naturally occurring ACAT inhibitor with acetogenin-type skeleton, was accomplished starting from both the enantiomers of ethyl 3-hydroxy butanoate 3. Stereochemistry of synthetic samples 1 and pseudo-1 was unambiguously assigned by converting to the authentic compound. The absolute configuration of natural acaterin was determined as (4R, 1′R) by careful

  的acaterin所有可能的立体异构体的对映选择性合成1，天然存在的与荔枝内酯型骨架ACAT抑制剂，在实现了从3-羟基丁酸的两个对映异构体起始3。通过转换为真实化合物，可以明确分配合成样品1和假1的立体化学。天然acaterin的绝对构型确定为（4 - [R，1' - [R ），通过TLC行为和光谱和光学数据仔细比较。
• [EN] RELEASABLE CONJUGATES<br/>[FR] CONJUGUÉS LIBÉRABLES
  申请人：QUIAPEG PHARMACEUTICALS AB

  公开号：WO2018163131A1

  公开（公告）日：2018-09-13

  The present application provides compounds of Formula (B), or pharmaceutically acceptable salts thereof, wherein D is a residue of a biologically active drug, which underdo hydrolysis under physiological conditions to release the biologically active drug and which are useful in the treatment of disorders that could be beneficially treated with the drug.

  本申请提供了化合物的公式（B），或其药用盐，其中D是生物活性药物的残留物，在生理条件下经过水解释放出生物活性药物，并且对可能受益于该药物治疗的疾病具有用处。